In-vivo Anti-Cancer activity of Polysaccharide Conjugate on DLA Cell lines

Abstract

Cancer is a complex disease with various forms that affect individuals globally. Projections for 2040 suggest a concerning surge, with the global burden of cancer expected to reach 28.4 million cases, representing a substantial 47% increase compared to 2020. The main limitations to the use of 5-FU in cancer therapy are based on its high water content and low oral bioavailability. The conjugation with chitosan can overcome the limitations of the pure 5-FU, which include insufficient bio distribution and less systemic circulation.Therefore, the current research aimed to assess the in-vivo anti-cancer efficacy of the 5-Fluorouracil conjugate. When compare to the cancer control, the results showed a significant decrease WBC and an increase in RBC count and haemoglobin levels after treatment with the conjugate.Moreover, treatment with the 5-FU combination resulted in a significant increase in the levels of anti-oxidant parameters like glutathione, nitric oxide, catalase, and superoxide dismutase.